Skip to main content

Table 1 Description of the GWAS studies used in the primary analysis

From: Herpesvirus infections and Alzheimer’s disease: a Mendelian randomization study

Variable/phenotype

Sample size (cases/controls)

Case mean/median AAOa

Control mean/median AAEa

% female, cases/controls

Phenotype ascertainment

AD GWAS (secondary analysis)

21,982/41944

    

ADGC

14,428/14562

71.1

76.2

59.3/59.3

Autopsy or clinically confirmed from health care records

CHARGE

2137/13474

82.6

76.7

67.3/55.8

EADI

2240/6631

75.4

78.9

65/60.6

GERAD

3177/7277

73.0

51.0

64/51.8

Herpesvirus infection GWAS

 Chicken pox

107,769/15982

45–60

45–60

51.9/37.0

Self-report questionnaires; vaccinated individuals were excluded from the controls in the chickenpox study

 Shingles

16,711/118152

 > 60

45–60

55.4/48.4

 Cold sores

25,108/63332

45–60

45–60

52.0/45.2

 Mononucleosis

17,457/68446

45–60

45–60

60.5/50.3

  1. aThe 23andMe cohort did not provide the exact mean AAO or AAE in the infection GWAS; thus, we used the median age of their participants instead. AAE Age at examination or last follow-up, AAO Age at onset, AD Alzheimer disease, ADGC Alzheimer Disease Genetics Consortium, CHARGE Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium, EADI The European Alzheimer’s Disease Initiative, GERAD Genetic and Environmental Risk in AD, GWAS Genome-wide association studies